VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Aug 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-08-19

Reporting Person: Kewalramani Reshma (Director, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-19	Common Stock	P	5757	$195.14	Acquired	69511	Direct
2021-08-19	Common Stock	P	4243	$196.34	Acquired	73754	Direct

Footnotes

F1: Open market purchases reported on this line occurred at a weighted average price of $195.14 (range $194.63 to $195.50).

F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3: Open market purchases reported on this line occurred at a weighted average price of $196.34 (range $195.74 to $196.58).